Anti-Angiogenic and Anti-Inflammatory Effects of SERPINA3K on Corneal Injury

Xiaochen Liu, Zhirong Lin, Tong Zhou, Ronrong Zong, Hui He, Zhen Liu, Jian‐xing Ma, Zuguo Liu, Yueping ZhouPLoS 2011 · DOI

Abstract

SERPINA3K, a member of the serine proteinase inhibitor (SERPIN) family, shows significant therapeutic potential for treating corneal neovascularization (NV) and inflammation. In a rat alkali burn model, topical application of SERPINA3K (20 µg/eye/day) significantly reduced the area of NV and improved the inflammatory index compared to controls. Mechanistically, SERPINA3K rebalances the corneal environment by down-regulating pro-angiogenic (VEGF) and pro-inflammatory (TNF-α) factors while up-regulating anti-angiogenic (PEDF) and regenerative (EGFR) factors. These findings highlight SERPINA3K as a promising multi-target therapeutic for corneal injury.

Introduction

Corneal injuries, particularly chemical alkali burns, are a leading cause of visual impairment worldwide. Such injuries trigger a destructive cascade characterized by intense inflammation and corneal neovascularization (NV)—the abnormal growth of blood vessels into the clear cornea. This combination often leads to permanent scarring and blindness. Current treatments are frequently insufficient or associated with significant side effects. There is a critical need for "multi-target" molecules that can simultaneously suppress pathological vessel growth and inflammation while promoting epithelial healing. This study investigates SERPINA3K, a protein known for its protective effects in the retina, as a potential therapeutic agent for the cornea.

Methods

The study employed a rat alkali burn model and in vitro cell culture experiments. Male Wistar rats received a controlled alkali burn (1N NaOH) and were treated topically with SERPINA3K (20 µg/eye/day), BSA, or PBS for 7 days. Clinical outcomes were evaluated using slit-lamp microscopy to measure NV area and an inflammatory index to quantify redness and swelling. Fluorescein staining tracked corneal epithelial healing. Molecular changes were assessed via Western blotting and immunofluorescence for VEGF, TNF-α, PEDF, and EGFR. Additionally, the effects of SERPINA3K on Human Umbilical Vein Endothelial Cells (HUVEC) and Human Corneal Epithelial (HCE) cells were tested using MTT assays to measure cell viability and growth.

Results and Key Insights

Reduced Neovascularization and Inflammation

By day 8, SERPINA3K-treated eyes showed a significantly smaller area of blood vessel growth compared to PBS or BSA controls ($p < 0.001$). The inflammatory index was also significantly reduced by day 5 and remained lower through day 8. Histological analysis confirmed reduced corneal thickening and fewer infiltrating inflammatory cells in the SERPINA3K group.

Enhanced Epithelial Healing

Fluorescein sodium staining revealed that the epithelial defect was smaller and the corneal surface was smoother in SERPINA3K-treated eyes. This indicates that the treatment not only prevents damage but actively accelerates the repair of the eye's outermost layer.

Molecular Rebalancing: The VEGF:PEDF Seesaw

Corneal health depends on a delicate balance between pro-angiogenic (VEGF) and anti-angiogenic (PEDF) factors. SERPINA3K treatment shifted this balance by significantly decreasing levels of the pro-angiogenic factor VEGF and the pro-inflammatory cytokine TNF-α, while simultaneously increasing levels of the anti-angiogenic factor PEDF.

Cell-Specific Action and EGFR Up-regulation

In vitro tests showed that SERPINA3K inhibited the growth of vascular endothelial cells (HUVECs) but had no negative impact on corneal epithelial cells (HCEs). Crucially, the study identified a novel role for SERPINA3K in up-regulating EGFR expression in the corneal epithelium, providing a mechanistic basis for its pro-healing effects on the ocular surface.

Discussion and Future Directions

SERPINA3K acts as a potent dual-action agent, suppressing the "blindness-inducing" duo of inflammation and NV while actively promoting surface repair. Its ability to up-regulate EGFR represents a significant finding in corneal wound healing research. However, the exact signaling pathways through which SERPINA3K triggers this increase remain to be fully elucidated; authors suggest a potential link to the Wnt pathway.

While the rat model effectively mimics human pathology, translational research is needed to account for differences in human corneal thickness and healing kinetics. Future studies should also evaluate the long-term effects of SERPINA3K on preventing chronic fibrosis (scarring) and maintaining long-term corneal clarity.

Summary updated

Abstract

SERPINA3K is a member of the serine proteinase inhibitor (SERPIN) family. Here we evaluated the therapeutic effects of SERPINA3K on neovascularization and inflammation in a rat cornea alkali burn model that is commonly employed to study corneal wounding. Topical treatment of the injured rat cornea with SERPINA3K (20 µg/eye/day) for 7 days significantly decreased the neovascular area, compared with the groups treated with BSA or PBS. The SERPINA3K treatment also ameliorated the corneal inflammation as evaluated by the inflammatory index. Furthermore, SERPINA3K enhanced the recovery of corneal epithelium after the alkali injury. Toward the mechanism of action, SERPINA3K down-regulated the expression of the pro-angiogenic and pro-inflammatory factors, vascular endothelial growth factor and tumor necrosis factor-α and up-regulated the expression of the anti-angiogenic factor, pigment epithelium-derived factor. SERPINA3K specifically inhibited growth of vascular endothelial cells. Meanwhile, SERPINA3K significantly up-regulated the expression of EGFR in the corneal epithelium. These findings suggest that SERPINA3K has therapeutic potential for corneal inflammation and NV.
BibTeX
@inproceedings{liu2011anti,
  author = {Xiaochen Liu and Zhirong Lin and Tong Zhou and Ronrong Zong and Hui He and Zhen Liu and Jian‐xing Ma and Zuguo Liu and Yueping Zhou and Zuguo Liu and Yueping Zhou},
  title = {{Anti-Angiogenic and Anti-Inflammatory Effects of SERPINA3K on Corneal Injury}},
  booktitle = {PLoS},
  year = {2011},
  doi = {10.1371/journal.pone.0016712},
}
Figure